Inovio is bringing IMMUNO-INGENUITY™ to life and is reshaping the future of treating and preventing cancer and infectious diseases.Inovio’s technology platform is capable of activating antigen-specific immune responses. Aptly named ASPIRE™ (Antigen SPecific Immune REsponses), this unique technology is primed to change the way cancer and infectious disease are treated. With demonstrated efficacy in a Phase 2b trial, robust and targeted immune responses, a favorable safety profile, and a robust pipeline of product candidates across multiple disease states, the evidence to date is clear—ASPIRE is realizing the true promise of immunotherapy.
|Bank Name||Inovio Pharmaceuticals, Inc.|
|CEO||Dr. J. Joseph Kim|